Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Washington University School of Medicine
IRCCS Azienda Ospedaliero-Universitaria di Bologna
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Minia University
Pfizer
Università Cattolica di Milano
Eastern Cooperative Oncology Group
Fudan University
Fudan University
Ankara University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
National Institutes of Health Clinical Center (CC)
Sichuan Enray Pharmaceutical Sciences Company
AstraZeneca
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Arvinas Inc.
Fujian Medical University
National Institutes of Health Clinical Center (CC)
Institut du Cancer de Montpellier - Val d'Aurelle
University of Colorado, Denver
Hospices Civils de Lyon
Alliance for Clinical Trials in Oncology
Pfizer
Assiut University
Rigshospitalet, Denmark
Solve Therapeutics
University of Nebraska
Zhejiang University
Adela, Inc
Georgetown University
Georgetown University
University of California, San Francisco
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.